# EDGAR Filing Document

**Accession Number:** 0001472012
**File Stem:** 0001193125-26-088287
**Filing Date:** 2026-3
**Character Count:** 25724
**Document Hash:** f60681a3c5c988c86ea57d8045ba745a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-088287.hdr.sgml**: 20260303

**ACCESSION NUMBER**: 0001193125-26-088287

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260303

**DATE AS OF CHANGE**: 20260303

**EFFECTIVENESS DATE**: 20260303

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immunome Inc.
- **CENTRAL INDEX KEY:** 0001472012
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 770694340
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293971
- **FILM NUMBER:** 26714656

**BUSINESS ADDRESS:**
- **STREET 1:** 18702 N. CREEK PARKWAY
- **STREET 2:** SUITE 100
- **CITY:** BOTHELL
- **STATE:** WA
- **ZIP:** 98011
- **BUSINESS PHONE:** 610-321-3700

**MAIL ADDRESS:**
- **STREET 1:** 18702 N. CREEK PARKWAY
- **STREET 2:** SUITE 100
- **CITY:** BOTHELL
- **STATE:** WA
- **ZIP:** 98011

**As filed with the Securities and Exchange Commission on March 3, 2026** 

**Registration No. 333-**

------

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER*** 

***THE SECURITIES ACT OF 1933*** 

------

**IMMUNOME, INC.** 

**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **77-0694340** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

**18702 N. Creek Parkway, Suite 100**

**Bothell, WA 98011**

**(Address of Principal Executive Offices)** 

**Immunome, Inc. 2020 Equity Incentive Plan**

**Immunome, Inc. 2020 Employee Stock Purchase Plan**

**Immunome, Inc. 2024 Inducement Plan**

**(Full titles of the plans)** 

**Clay Siegall, Ph.D.**

**Chief Executive Officer** 

**Immunome, Inc.** 

**18702 N. Creek Parkway, Suite 100**

**Bothell, WA 98011**

**(425) 939-7410**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

**Copies to:** 

**Thomas A. Coll, Esq.**

**Carlos Ramirez, Esq.**

**Dylan Kornbluth, Esq.** 

**Cooley LLP** 

**10265 Science Center Drive**

**San Diego, California 92121** 

**Tel: (858) 550-6000** 

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE**

This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of the registrant on Form S-8 relating to the same employee benefit plans are effective.

The registrant previously registered shares of its Common Stock for issuance under its 2020 Equity Incentive Plan (the "2020 Plan) and 2020 Employee Stock Purchase Plan (the "2020 ESPP") under Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the "Commission") on [<u>March 25, 2021 (File No. 333-254731)</u>](https://www.sec.gov/Archives/edgar/data/1472012/000110465921041594/tm2110963d1_s8.htm), [<u>March 16, 2023 (File No. 333-270598)</u>](https://www.sec.gov/Archives/edgar/data/1472012/000110465923033088/tm239583d2_s8.htm), and [<u>February 2, 2024 (File No. 333-276839)</u>](https://www.sec.gov/Archives/edgar/data/1472012/000110465924010014/tm244955d1_s8.htm). Additionally, the registrant previously registered shares of its Common Stock for issuance under its 2020 Plan, 2020 ESPP and 2024 Inducement Plan under a Registration Statement on Form S-8 filed with the Commission on [<u>March 19, 2025 (File No. 333-285930)</u>](https://www.sec.gov/Archives/edgar/data/1472012/000110465925025642/tm259725d2_s8.htm). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3. Incorporation of Documents by Reference.** 

The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)The registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on [<u>March 3, 2026</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)The information specifically incorporated by reference into the Registrant's Annual Report on Form 10-K from the Registrant's Definitive Proxy Statement on [<u>Schedule 14A</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001472012/000114036125015421/ny20045110x1_def14a.htm)filed with the SEC on April 24, 2025; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)The description of the Registrant's Common Stock set forth in the Registration Statement on [<u>Form 8-A</u>](https://www.sec.gov/Archives/edgar/data/1472012/000110465920110396/tm2032140-1_8a12b.htm) filed with the Commission on September 30, 2020, including any amendments or reports filed for the purpose of updating such description.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information, or portions thereof, which are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

------

**Item 8. Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 4.1 | [<u>Amended and Restated Certificate of Incorporation of the Registrant (Filed as Exhibit 3.1 to Registrant's Current Report on Form 8-K filed with the Commission on October 6, 2020 and incorporated herein by reference).</u>](https://www.sec.gov/Archives/edgar/data/1472012/000110465920112632/tm2032458d1_ex3-1.htm) |
| 4.2 | [<u>Certificate of Amendment, dated October 2, 2023 to the Amended and Restated Certificate of Incorporation of Immunome, Inc. to implement Officer Exculpation (Filed as Exhibit 3.3 to the Registrant's Current Report on Form 8-K filed with the Commission on October 4, 2023 and incorporated herein by reference).</u>](https://www.sec.gov/Archives/edgar/data/1472012/000110465923106592/tm2327438d1_ex3-3.htm) |
| 4.3 | [<u>Certificate of Amendment, dated October 2, 2023 to the Amended and Restated Certificate of Incorporation of Immunome, Inc. to implement the Authorized Share Increase (Filed as Exhibit 3.4 to the Registrant's Current Report on Form 8-K filed with the Commission on October 4, 2023 and incorporated herein by reference).</u>](https://www.sec.gov/Archives/edgar/data/1472012/000110465923106592/tm2327438d1_ex3-4.htm) |
| 4.4 | [<u>Amended and Restated Bylaws of the Registrant (Filed as Exhibit 3.2 to Registrant's Current Report on Form 8-K filed with the Commission on October 6, 2020 and incorporated herein by reference).</u>](https://www.sec.gov/Archives/edgar/data/1472012/000110465920112632/tm2032458d1_ex3-2.htm) |
| 4.5 | [<u>Form of Common Stock Certificate (Filed as Exhibit 4.2 to Amendment No. 1 to Registrant's Registration Statement on Form S-1/A filed on September 24, 2020 and incorporated herein by reference).</u>](https://www.sec.gov/Archives/edgar/data/1472012/000110465920108076/tm2025599d7_ex4-2.htm) |
| 5.1\* | [<u>Opinion of Cooley LLP.</u>](imnm-ex5_1.htm) |
| 23.1\* | [<u>Consent of Independent Registered Public Accounting Firm.</u>](imnm-ex23_1.htm) |
| 23.2\* | [<u>Consent of Cooley LLP (included in Exhibit 5.1).</u>](imnm-ex5_1.htm) |
| 24.1\* | [<u>Power of Attorney (included on signature page).</u>](#power_of_attorney) |
| 99.1+ | [<u>2020 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on November 9, 2023)</u>](https://www.sec.gov/Archives/edgar/data/1472012/000155837023018425/tmb-20230930xex10d1.htm). |
| 99.2+ | [<u>Forms of Executive and Non-Executive Stock Option Grant Notice, Option Agreement and Notice of Exercise for the 2020 Equity Incentive Plan (Filed as Exhibit 10.7 to Registrant's Annual Report on Form 10-K filed with the Commission on March 19, 2025 and incorporated herein by reference).</u>](https://www.sec.gov/Archives/edgar/data/0001472012/000155837025003302/tmb-20241231xex10d7.htm) |
| 99.3+ | [<u>Immunome, Inc. 2024 Inducement Plan, as amended, and Forms of Executive and Non-Executive Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder (incorporated by reference in Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on August 6, 2025).</u>](https://www.sec.gov/Archives/edgar/data/1472012/000095017025104035/imnm-ex10_1.htm)<br>|
| 99.4+ | [<u>Immunome, Inc. 2020 Employee Stock Purchase Plan (Filed as Exhibit 10.8 to Amendment No. 1 to Registrant's Registration Statement on Form S-1/A filed with the Commission on September 24, 2020 and incorporated herein by reference).</u>](https://www.sec.gov/Archives/edgar/data/1472012/000110465920108076/tm2025599d7_ex10-8.htm) |
| 107\* | [<u>Filing Fee Table.</u>](imnm_exfilingfees.htm) |

---

------

\* Filed herewith.

+ Denotes management contract or compensatory plan or arrangement.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bothell, State of Washington, on March 3, 2026.

---

| | |
|:---|:---|
| **IMMUNOME, INC.** | **IMMUNOME, INC.** |
| By: | /s/ Clay Siegall |
|  | Clay Siegall, Ph.D. |
|  | Chief Executive Officer |

---

**POWER OF ATTORNEY** 

**KNOW ALL PERSONS BY THESE PRESENTS,** that each person whose signature appears below constitutes and appoints Clay Siegall, Ph.D. and Max Rosett, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Clay Siegall | President, Chief Executive Officer and Chairman of the Board of Directors | March 3, 2026 |
| Clay Siegall, Ph.D. | (*Principal Executive Officer*) | March 3, 2026 |
| /s/ Max Rosett | Chief Financial Officer  | March 3, 2026 |
| Max Rosett | (*Principal Financial and Accounting Officer*) | March 3, 2026 |
| /s/ Isaac Barchas | Director | March 3, 2026 |
| Isaac Barchas | Director | March 3, 2026 |
| /s/ Jean-Jacques Bienaimé | Director | March 3, 2026 |
| Jean-Jacques Bienaimé | Director | March 3, 2026 |
| /s/ James Boylan | Director | March 3, 2026 |
| James Boylan | Director | March 3, 2026 |
| /s/ Carol Schafer  | Director | March 3, 2026 |
| Carol Schafer | Director | March 3, 2026 |
| /s/ Sandra M. Swain  | Director | March 3, 2026 |
| Sandra M. Swain, M.D. | Director | March 3, 2026 |
| /s/ Philip Wagenheim | Director | March 3, 2026 |
| Philip Wagenheim | Director | March 3, 2026 |

---

------

## Exhibit 5.1

Cooley LLP 10265 Science Center Drive San Diego, CA 92121<br>t: (858) 550-6000 f: (858) 550-6420 cooley.com

**Exhibit 5.1**

![img259784093_0.jpg](img259784093_0.jpg)

Thomas A. Coll

+1 858 550 6013

collta@cooley.com

March 3, 2026

Immunome, Inc.

18702 N. Creek Parkway, Suite 100

Bothell, WA 98011

Ladies and Gentlemen:

We have acted as counsel to Immunome, Inc., a Delaware corporation (the "***Company***"), in connection with the filing by the Company of a Registration Statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") covering the offering of up to 7,025,327 shares (the "***Shares***") of the Company's Common Stock, $0.0001 par value per share (the "***Common Stock***"), consisting of (i) 4,525,327 shares of Common Stock issuable pursuant to the Company's 2020 Equity Incentive Plan (the "***Incentive Plan***"), (ii) 1,000,000 shares of Common Stock issuable pursuant to the Company's 2020 Employee Stock Purchase Plan (the, "***ESPP***"), and (iii) 1,500,000 shares of Common Stock issuable pursuant to the Company's 2024 Inducement Plan (together with the Incentive Plan and the ESPP, the "***Plans***").

In connection with this opinion, we have examined and relied upon (i) the Registration Statement and related prospectuses, (ii) the Plans, (iii) the Company's certificate of incorporation and bylaws, each as currently in effect, and (iv) such other records, documents, opinions certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than by the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and the related prospectuses, will be validly issued, fully paid and nonassessable (except as to shares issued pursuant to deferred payment arrangements under the Incentive Plan, which will be fully paid and nonassessable when such deferred payments are made in full).

------

Cooley LLP 10265 Science Center Drive San Diego, CA 92121<br>t: (858) 550-6000 f: (858) 550-6420 cooley.com

---

| |
|:---|
| &nbsp;&nbsp;![img259784093_0.jpg](img259784093_0.jpg) |
| &nbsp;&nbsp;March 3, 2026<br>Page Two |

---

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this letter to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Sincerely,

Cooley LLP

By: <u>/s/ Thomas A. Coll</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thomas A. Coll

------

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2020 Equity Incentive Plan, 2020 Employee Stock Purchase Plan, and 2024 Inducement Plan of Immunome, Inc. of our report dated March 3, 2026, with respect to the consolidated financial statements of Immunome, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Philadelphia, Pennsylvania

March 3, 2026

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

**Exhibit 107**

**Calculation of** Filing Fee **Tables**

Immunome, Inc.

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Security<br>Type | **Security Class Title**  | **Fee<br>Calculation<br>Rule** | **Amount<br>Registered** | **Proposed<br>Maximum<br>Offering<br>Price Per<br>Unit** | **Maximum<br>Aggregate<br>Offering<br>Price** | **Fee Rate** | **Amount of<br>Registration<br>Fee** |
| 1  | Equity | 2020 Equity Incentive Plan, Common Stock, $0.0001 par value per share  | Other | 4525327 | $22.39 | $101322071.53 | 0.0001381 | $13992.58 |
| 2  | Equity | 2024 Inducement Plan, Common Stock, $0.0001 par value per share | Other | 1500000 | $22.39 | $33585000.00 | 0.0001381 | $4638.09 |
| 3  | Equity | 2020 Employee Stock Purchase Plan, Common Stock, $0.0001 par value per share | Other | 1000000 | $19.03 | $19030000.00 | 0.0001381 | $2628.04 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $153937071.53 |  | $21258.71 |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00 |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $21258.71 |
| **Offering Note** | **Offering Note** | **Offering Note** | **Offering Note** |  |  |  |  |  |

---

1. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover additional shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Immunome, Inc. (the "Registrant") that become issuable under the Registrant's 2020 Equity Incentive Plan (the "2020 Plan") by reason of any stock dividend, stock split, recapitalization or other similar transaction. The amount registered represents additional shares of Common Stock reserved for future grant under the 2020 Plan as a result of the automatic increase in shares reserved thereunder on January 1, 2026 pursuant to the terms of the 2020 Plan. The 2020 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2020 Plan on January 1 of each calendar year through (and including) January 1, 2030, in an amount equal to the lesser of (a) 4% of the total number of shares of capital stock of the Registrant outstanding on December 31st of the preceding calendar year; or (b) a lesser number of shares of Common Stock as the Registrant's board of directors (the "Board") may designate no later than December 31st of the immediately preceding year. The proposed maximum offering price per unit and maximum aggregate offering price are estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) of the Securities Act using the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Capital Market on February 24, 2026.

------

2. Pursuant to Rule 416(a) under the Securities Act, this registration statement shall also cover additional shares of Common Stock of the Registrant that become issuable under the Registrant's 2024 Inducement Plan (as amended, the "Inducement Plan") by reason of any stock dividend, stock split, recapitalization or other similar transaction. The amount registered represents additional shares of Common Stock that were added to the shares authorized for issuance under the Inducement Plan pursuant to an amendment to the Inducement Plan approved by the Compensation Committee of the Board on May 8, 2025. The proposed maximum offering price per unit and maximum aggregate offering price are estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) of the Securities Act using the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Capital Market on February 24, 2026.

3. Pursuant to Rule 416(a) under the Securities Act, this registration statement shall also cover additional shares of Common Stock of the Registrant that become issuable under the Registrant's 2020 Employee Stock Purchase Plan (the "2020 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction. The amount registered represents additional shares of Common Stock that were automatically added to the shares authorized for issuance under the 2020 ESPP on January 1, 2026 pursuant to an "evergreen" provision contained in the 2020 ESPP. The 2020 ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2020 ESPP on January 1 of each calendar year through (and including) January 1, 2030. The number of shares of Common Stock added each year will be equal to the lesser of: (a) 1% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year; (b) 1,000,000 shares; or (c) such lesser number of shares of Common Stock as the Board may designate no later than December 31st of the immediately preceding year. The proposed maximum offering price per unit and maximum aggregate offering price are estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) of the Securities Act using the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Capital Market on February 24, 2026, multiplied by 85%. Pursuant to the 2020 ESPP, the purchase price of the shares of Common Stock will be 85% of the lesser of the fair market value of the Common Stock on the Offering Date or the Purchase Date (each as defined in the 2020 ESPP).

---

| | |
|:---|:---|
| **Table 2: Fee Offset Claims and Sources** | **☑Not Applicable** |

---

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Registrant<br>or Filer<br>Name**  | **Form<br>or<br>Filing<br>Type** | **File<br>Number** | **Initial<br>Filing<br>Date** | **Filing<br>Date** | **Fee<br>Offset<br>Claimed** | **Security<br>Type<br>Associated<br>with Fee<br>Offset<br>Claimed** | **Security<br>Title<br>Associated<br>with Fee<br>Offset<br>Claimed** | **Unsold<br>Securities<br>Associated<br>with Fee<br>Offset<br>Claimed** | **Unsold<br>Aggregate<br>Offering<br>Amount<br>Associated<br>with Fee<br>Offset<br>Claimed** | **Fee<br>Paid<br>with<br>Fee<br>Offset<br>Source** |
| **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  |
| Fee Offset Sources  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  |

---

------